ATH434
ATH434 has been studied in 2 papers since 2021: none in people yet, 2 in animals. The research so far is in animals. The newest paper, Sep 29, 2022: “ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism”.
2 papers study it7 findingsUpdated
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country; 4 trials, none about aging, 2 with no results posted.
None of its findings points the other way.
- 1 lab in 1 country
- 4 trials, none about aging, 2 with no results posted
- Funders: University of Melbourne and 4 more
- 3 of 4 trials sponsored by its developers
- Animals2
What did studies of ATH434 find?
7Studies of ATH434 measured 7 outcomes, among them substantia nigra neurodegeneration, motor impairment and bulbar iron and copper.
Substantia nigra neurodegeneration
downin mice1
1 study
Substantia nigra neurodegeneration
downin mice1
ATH434 decreases substantia nigra neurodegeneration in mice (tau knockout mice).
“which coincided with a reduction in iron levels and reduced neurodegeneration in the substantia nigra.”
Animalstau knockout micesubstantia nigra30 mg/kg/day6 weeks
ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Motor impairment
downin mice1
1 study
Motor impairment
downin mice1
ATH434 prevents motor impairment in mice (tau knockout mice).
“ATH434 was able to prevent the development of motor impairment in aged tau-/- mice”
Animalstau knockout mice30 mg/kg/day6 weeks
ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Bulbar iron and copper
downin mice1
1 study
Bulbar iron and copper
downin mice1
ATH434 decreases bulbar iron and copper in mice (tau knockout mice).
“which coincided with a reduction in bulbar iron and copper levels”
Animalstau knockout miceolfactory bulb30 mg/kg/day6 weeks
ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Hyposmia
downin mice1
1 study
Hyposmia
downin mice1
ATH434 prevents hyposmia in mice (tau knockout mice).
“ATH434 was able to prevent the development of hyposmia in young tau-/- mice”
Animalstau knockout mice30 mg/kg/day6 weeks
ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Proportion of neurons with nuclear Hu+ translocation
downin mice1
1 study
Proportion of neurons with nuclear Hu+ translocation
downin mice1
ATH434 decreases proportion of neurons with nuclear Hu+ translocation in mice (A53T alpha-synuclein transgenic mice; treatment and prevention groups).
“was reduced in both groups when ATH434 was administered.”
AnimalsA53T alpha-synuclein transgenic mice; treatment and prevention groupsenteric nervous system30 mg/kg/day3 or 4 months
ATH434 Reverses Colorectal Dysfunction in the A53T Mouse Model of Parkinson's Disease
Journal of Parkinson's disease
More on Proportion of neurons with nuclear Hu+ translocation
Gut transit time
no changein mice1
1 study
Gut transit time
no changein mice1
ATH434 showed no clear effect on gut transit time in mice.
“did not alter deficits in gut transit time when compared to vehicle-treated A53T mice.”
AnimalsA53T alpha-synuclein transgenic mice treated before slowed propulsion; compared with vehicle-treated A53T micegut30 mg/kg/day3 months
ATH434 Reverses Colorectal Dysfunction in the A53T Mouse Model of Parkinson's Disease
Journal of Parkinson's disease
Colonic propulsion
upin mice1
1 study
Colonic propulsion
upin mice1
ATH434 improves colonic propulsion in mice (A53T alpha-synuclein transgenic mice with established dysfunction) (Restored to WT levels).
“ATH434, given after dysfunction was established, resulted in a reversal of slowed colonic propulsion and gut transit deficits in A53T mice to WT levels.”
AnimalsA53T alpha-synuclein transgenic mice with established dysfunctioncolon30 mg/kg/day4 months
ATH434 Reverses Colorectal Dysfunction in the A53T Mouse Model of Parkinson's Disease
Journal of Parkinson's disease
Who is developing ATH434?
1 company: Alterity Therapeutics.
- Companies
- Alterity TherapeuticsPhase 2multiple system atrophy
Trial sponsors
Company2 trialsPhase 217 people
Company1 trialPhase 210 people